NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix provides second quarter operational and financial update
    Nanobiotix Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
    Nanobiotix Reports New Data for Potential First-In-Class Radio­enhancer NBTXR3 in Combination with Anti-Pd-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-Pd-1 Exposure



    August 27, 2021

    ESTRO 2021

    More info
    July 22, 2021

    AHNS 10th International Conference on Head and Neck Cancer

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation